Last reviewed · How we verify

NCT06902493

Impact of Prior SGLT2 Inhibitors Use on the Development and Progression of Sepsis-Associated Acute Kidney Injury

Completed Last updated 30 March 2025
What this trial tests

trial testing No intervention in Sepsis in 664 participants. Completed in 1 March 2025.

Timeline
1 April 2024
Primary endpoint
1 March 2025
1 March 2025

Quick facts

Lead sponsorUniversity of Jazan
StatusCompleted
Study typeOBSERVATIONAL
Enrollment664
Start date1 April 2024
Primary completion1 March 2025
Estimated completion1 March 2025
Sites1 location across Saudi Arabia

Drugs / interventions tested

Conditions studied

Sponsor

University of Jazan

Who can join

Adults 18 to 75, any sex, with Sepsis or Septic Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to investigate whether using SGLT2i may be associated with decreased incidence of sepsis-induced AKI or not.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Sepsis

Currently open trials in the same condition.

Other University of Jazan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06902493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing